11:39 AM EST - Cardiome Pharma Corp. : Announced that one of its subsidiaries has entered into an agreement with Chong Kun Dang Pharmaceuticals ("CKD") to commercialize BRINAVESS® (vernakalant HCl) in South Korea. CKD will be responsible for obtaining the regulatory approval required to commercialize BRINAVESS in South Korea. Cardiome Pharma Corp.
shares T.COM are trading unchanged at $11.00.
